News Analysis

PrEP for HIV is a pill. It has always been a pill. But it will not always be a pill, thanks to two major trials evaluating cabotegravir, an integrase inhibitor formulated for intramuscular injection, as PrEP.

An important new analysis describes a key barrier to PrEP in the U.S., one that is almost sinister in its application predominantly in southern states.

IPERGAY scientists recommended that clinicians screen patients who request PrEP, as well as patients who are already using it, for a number of key HCV risk factors.

Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.

Pre-exposure prophylaxis (PrEP) is a vital part of ending HIV, but ads targeting people to join lawsuits are planting needless fears in patients, three leading HIV specialists write.

Pharmacists will increasingly play a role in pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) access in California.

The ECHO trial faces backlash and criticism.

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

"A lot of patients want to know, 'Who else is going to see this data?'" said Peter Chai of Fenway Health in Boston.

New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.